U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
NEW YORK, April 25, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased BioAmber Inc. (“BioAmber”) (NYSE:BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/bioamber-inc?wire=3. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/bioamber-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
